Education
About Us
Working with TipRanks
Follow Us
Synairgen PLC (GB:SNG)
LSE:SNG
SNG Stock Chart & Stats
Day’s Range― - ―
52-Week Range0.60p - 7.22p
Previous CloseN/A
Volume2.74M
Average Volume (3M)1.19M
Market Cap
£9.92M
Enterprise Value-133.25K
Total Cash (Recent Filing)£5.28K
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta2.76
Next Earnings
Sep 25, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding1,102,660,600
10 Day Avg. Volume1,580,454
30 Day Avg. Volume1,185,593
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Synairgen News
PremiumCompany Announcements
Synairgen to Re-register as Private Company and Delist from AIM
PremiumCompany Announcements
Synairgen to Delist from AIM and Re-register as Private Company
PremiumCompany Announcements
TFG Asset Management Increases Stake in Synairgen
PremiumCompany Announcements
Synairgen Secures £18 Million Funding Amidst AIM Delisting Plans
PremiumCompany Announcements
Synairgen Strengthens Board with Appointment of Martin Murphy
PremiumCompany Announcements
Synairgen Secures £18 Million for Phase 2 Trial of SNG001
PremiumCompany Announcements
Synairgen Launches Fundraising to Advance Respiratory Treatment TrialsPremiumCompany Announcements
Synairgen Expands Share Capital with New Issuance---
SNG FAQ
What was Synairgen PLC’s price range in the past 12 months?
Synairgen PLC lowest share price was 0.60p and its highest was 7.22p in the past 12 months.
What is Synairgen PLC’s market cap?
Synairgen PLC’s market cap is £9.92M.
When is Synairgen PLC’s upcoming earnings report date?
Synairgen PLC’s upcoming earnings report date is Sep 25, 2025 which is in 176 days.
How were Synairgen PLC’s earnings last quarter?
Currently, no data Available
Is Synairgen PLC overvalued?
According to Wall Street analysts Synairgen PLC’s price is currently Overvalued.
Does Synairgen PLC pay dividends?
Synairgen PLC does not currently pay dividends.
What is Synairgen PLC’s EPS estimate?
Synairgen PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Synairgen PLC have?
Synairgen PLC has 1,102,660,600 shares outstanding.
What happened to Synairgen PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Synairgen PLC?
Currently, no hedge funds are holding shares in GB:SNG
---
Company Description
Synairgen PLC
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
---
Technical Analysis
---